View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
January 14, 2022

Burden of brain cancer will continue to rise in the US ageing population

GlobalData epidemiologists forecast that more than half of all newly diagnosed cases in the US are in the age 60 and older population.

By GlobalData Healthcare

Brain cancer is a very severe and often highly debilitating disease that has become the subject of a great deal of research. Although the disease is not as common as many other cancer types, and some forms of brain cancer are considered rare, the disease has been well-documented and discussed over the past decade. Brain cancer is known to be more common in men than in women and shows a bimodal distribution, with an increased incidence among children and an increasing incidence with age. GlobalData epidemiologists forecast that more than half of all newly diagnosed cases in the US are in the age 60 years and older population, and this burden will continue in the near future.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of brain cancer in the US from 27,000 diagnosed incident cases in 2020 to 31,000 diagnosed incident cases in 2030, at an annual growth rate (AGR) of 1.50%. In the US, 55–60% of newly diagnosed cases during the forecast period were in ages 60 years and older, and the age distribution of cases was similar in the male and female population.

Brain Cancer is a malignant cancer that originates in the central nervous system, which consists of the brain and spinal cord, including the brain stem. The type and severity of a brain tumor is determined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth. The growth rate and location of a brain tumor determines its effect on the functioning of the nervous system. Brain cancer does not have any specific risk factor except age and familial history, although radiation exposure has been identified as a risk in some instances. However, brain cancer is strongly associated with common comorbidities such as hypertension, diabetes, and heart disease. This is probably due to wide prevalence of these comorbidities especially in the older population.

Brain cancer has a moderately poor survival rate, where 60% of the cases survive the first year of diagnosis and only 30% of the cases survive beyond the fifth year of diagnosis. The survival rate has improved slightly, over the last 10 years especially with cases diagnosed in the earlier stages. However, the growing aging population suggests that the overall number of people with brain cancer will continue to rise in the near future. Currently, early diagnosis of brain cancer is difficult due to a lack of clear diagnostic tools, which partly explains the low survival rate. In recent years, lots of research have been conducted into biomarkers such as IDH1/IDH2, NTRK, and BRAF-V600E, which will help detect the disease earlier and predict the prognosis. These biomarkers could also shed light on why certain populations are more susceptible to brain cancer.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena